Patient-Derived Prostate Cancer: from Basic Science to the Clinic
Systems that model cancer form the backbone of research discovery, and their accuracy and validity are a key determinant to ensure successful translation. In many tumour types, patient-derived specimens are an important model of choice for pre-clinical drug development. In this review, we consider why this has been such a challenge for prostate cancer, resulting in relatively few patient-derived xenografts (PDXs) of prostatic tumours compared to breast cancers, for example. Nevertheless, with only a few patient specimens and PDXs, we exemplify in three vignettes how important new clinical insights were obtained resulting in benefit for future men with prostate cancer.
KeywordsProstate Cancer Androgen Receptor Neuroendocrine Carcinoma BRCA2 Mutation Carrier Abiraterone
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
GP Risbridger and RA Taylor are supported by research fellowships from the National Health and Medical Research Council of Australia (ID: 1102752) and the Victorian Cancer Agency (MCRF15023).
- 16.Wang Y et al. (2015) Subrenal capsule grafting technology in human cancer modeling and translational cancer research. DifferentiationGoogle Scholar
- 22.Alsop K et al. (2016) An effective community based model of rapid autopsy in end-stage cancer patients. Nat Biotechnol, (Accepted for Publication)Google Scholar
- 25.Buhler KR, QJ, Liu AY, Wang H, Ellis WJ, Vessella RL (1997) LuCaP 35: an androgen inducible, prostate-specific antigen producing human prostate cancer xenograft. Proc Am Assoc Cancer Res (38:1600)Google Scholar
- 28.Valta MP et al. (2016) Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer. Clin Exp MetastasisGoogle Scholar
- 38.Beltran H et al. (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat MedGoogle Scholar
- 40.Kumar A et al. (2016) Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat MedGoogle Scholar